EPS Reference Time Actual Consensus Previous
2026-10-22 FY2026Q3 PM 1.02 0.92
2026-07-30 FY2026Q2 PM 1.19 0.96 1.01
2026-04-30 FY2026Q1 PM 0.86 0.89 0.86
2026-02-24 FY2025Q4 PM 1.04 0.95 0.93
2025-10-30 FY2025Q3 PM 0.92 0.83 0.86



Peers Price Chg Day Year Date
Terumo 2,572.00 -24.50 -0.94% -3.90% Aug/26
Olympus 2,133.00 -33.00 -1.52% 22.16% Aug/26
Abbott 116.13 -0.54 -0.46% -11.75% Aug/25
AngioDynamics 15.95 0.18 1.14% 62.92% Aug/25
Anika Therapeutics 21.40 0.06 0.28% 129.37% Aug/25
AtriCure 48.68 -0.60 -1.22% 28.55% Aug/25
Baxter International 26.29 -0.20 -0.76% 7.31% Aug/25
Becton, Dickinson and Co. 189.78 -0.96 -0.50% -2.21% Aug/25
Boston Scientific 49.86 0.85 1.73% -53.13% Aug/25
Cooper Companies 73.04 -2.76 -3.64% -0.84% Aug/25

Indexes Price Day Year Date
USND 26151 171.11 0.66% 21.38% Aug/25
US2000 3010 14.94 0.50% 27.62% Aug/25

Merit Medical Systems traded at $91.09 this Tuesday August 25th, increasing $0.81 or 0.90 percent since the previous trading session. Looking back, over the last four weeks, Merit Medical Systems gained 19.70 percent. Over the last 12 months, its price rose by 2.28 percent. Looking ahead, we forecast Merit Medical Systems to be priced at 88.84 by the end of this quarter and at 83.26 in one year, according to Trading Economics global macro models projections and analysts expectations.

Merit Medical Systems, Inc. designs, develops, manufactures and markets medical products for interventional and diagnostic procedures. The Company’s segments include cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, breast cancer localization and guidance, biopsy, interventional oncology and spine devices. The endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products, including peripheral intervention, cardiac intervention, custom procedural solutions, original equipment manufacturer and endoscopy.